KLRK1 and glioblastoma: NK cells expressing dual CARs targeting GD2 and NKG2D ligands showed improved recognition of glioblastoma (GBM) cells, achieving a ~2-fold reduction in tumor volume and weight compared to single CAR-treated mice [9].